Affinity: Home blood count monitoring for personalised delivery of cancer therapy

Affinity：家庭血细胞计数监测，用于个性化癌症治疗

• 批准号: 104471
• 金额: $ 151.84万
• 依托单位: ENTIA LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104471
• 关键词: Affinity; Home; blood; count; monitoring

"50% of people are expected to get cancer at some point in their life. Even with new therapies, many patients will experience unwanted side effects from their treatment that may range from minor psychological issues through to life threatening infections. With cancer patients spending a significant amount of time outside of healthcare facilities, it becomes hard to identify early changes that may lead to such complications. This project shall be the final stage of development for a new home monitoring technology that can reduce unnecessary hospital visits for patients, improve the management of side effects, enhance quality of life and reduce the likelihood of life-threatening adverse events occurring. This platform will operate by allowing recipients of systemic cancer therapy to monitor their blood counts and symptoms within their home whilst sharing that information with their nurses and doctors through a real-time connection that is integrated directly with their care provider. Earlier development work has been undertaken with patients, carers, nurses and clinicians using human centered design processes to ensure that the technology is easy to use and solves genuine problems for people receiving systemic cancer therapy. This project brings together two of the UK's leading hospital trusts, The Royal Marsden NHS Foundation Trust and The Christie NHS Foundation Trust alongside The University of Manchester, Imperial College Health Partners, Entia and iQ Healthtech to ensure this innovation can be rapidly adopted across healthcare."

50%的人预计会在一生中的某个时候患上癌症。即使有了新的治疗方法，许多患者也会在治疗中体验到不想要的副作用，从轻微的心理问题到危及生命的感染。由于癌症患者在医疗机构外花费的时间很长，因此很难确定可能导致此类并发症的早期变化。该项目将是开发一种新的家庭监测技术的最后阶段，该技术可以减少患者不必要的住院次数，改善副作用的管理，提高生活质量，并减少发生危及生命的不良事件的可能性。该平台将允许接受系统性癌症治疗的人在家中监测他们的血细胞计数和症状，同时通过与护理提供者直接集成的实时连接与他们的护士和医生共享这些信息。早期的开发工作已经进行，患者、护理人员、护士和临床医生使用以人为中心的设计流程，以确保该技术易于使用，并为接受系统性癌症治疗的人解决真正的问题。该项目汇集了英国两家领先的医院信托基金--皇家马斯登NHS基金会信托基金和克里斯蒂NHS基金会信托基金，以及曼彻斯特大学、帝国学院健康合作伙伴、ens和IQ Healthtech，以确保这项创新可以在医疗保健领域迅速采用。“